AR081752A1 - Formas polimorficas del acido 1-(3’,4’-dicloro-2-fluorobifenil-4-il)ciclopropano carboxilico, sus sales y composiciones farmaceuticas - Google Patents

Formas polimorficas del acido 1-(3’,4’-dicloro-2-fluorobifenil-4-il)ciclopropano carboxilico, sus sales y composiciones farmaceuticas

Info

Publication number
AR081752A1
AR081752A1 ARP110101069A ARP110101069A AR081752A1 AR 081752 A1 AR081752 A1 AR 081752A1 AR P110101069 A ARP110101069 A AR P110101069A AR P110101069 A ARP110101069 A AR P110101069A AR 081752 A1 AR081752 A1 AR 081752A1
Authority
AR
Argentina
Prior art keywords
fluorobiphenyl
dichloro
carboxylic cyclopropane
salts
carboxylic
Prior art date
Application number
ARP110101069A
Other languages
English (en)
Inventor
Maurizio Delcanale
Marco Curzi
Stefano Luca Giaffreda
Fausto Pivetti
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of AR081752A1 publication Critical patent/AR081752A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/16—Unsaturated compounds
    • C07C61/40—Unsaturated compounds containing halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Tres formas polimórficas y varias sales del ácido 1-(3’,4’-dicloro-2-fluorobifenil-4-il)ciclopropano carboxílico, y su uso en la prevención o el tratamiento de la enfermedad de Alzheimer.Reivindicación 1: Un polimorfo cristalino (Forma I) del ácido 1-(3’,4’-dicloro-2-fluorobifenil-4-il)ciclopropano carboxílico caracterizado porque tiene un patrón de difracción de rayos X en polvo que comprende picos característicos expresados en ángulos 2-q a aproximadamente: Reivindicación 3: Un polimorfo cristalino (Forma II) del ácido 1-(3’,4’-dicloro-2-fluorobifenil-4-il)ciclopropano carboxílico caracterizado porque tiene un patrón de difracción de rayos X en polvo que comprende picos característicos expresados en ángulos 2-qtheta a aproximadamente: Reivindicación 5: Un polimorfo cristalino (Forma III) del ácido 1-(3’,4’-dicloro-2-fluorobifenil-4-il)ciclopropano carboxílico caracterizado porque tiene un patrón de difracción de rayos X en polvo que comprende picos característicos expresados en ángulos 2-q a aproximadamente: Reivindicación 7: Una sal del ácido 1-(3’,4’-dicloro-2-fluorobifenil-4-il)ciclopropano carboxílico caracterizada porque se selecciona entre el grupo que consiste en sales de Na, K, Ca, L-arginina, D-arginina, y L-Iisina. Reivindicación 8: Una composición farmacéutica caracterizada porque comprende un polimorfo sustancialmente puro de acuerdo con cualquiera de las reivindicaciones 1 a 6 o una sal de acuerdo con la reivindicación 7, y un vehículo farmacéuticamente aceptable.
ARP110101069A 2010-04-01 2011-03-31 Formas polimorficas del acido 1-(3’,4’-dicloro-2-fluorobifenil-4-il)ciclopropano carboxilico, sus sales y composiciones farmaceuticas AR081752A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10158954 2010-04-01

Publications (1)

Publication Number Publication Date
AR081752A1 true AR081752A1 (es) 2012-10-17

Family

ID=44079474

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101069A AR081752A1 (es) 2010-04-01 2011-03-31 Formas polimorficas del acido 1-(3’,4’-dicloro-2-fluorobifenil-4-il)ciclopropano carboxilico, sus sales y composiciones farmaceuticas

Country Status (9)

Country Link
US (3) US8673978B2 (es)
EP (2) EP2647618A1 (es)
KR (1) KR20130036210A (es)
CN (2) CN102869643A (es)
AR (1) AR081752A1 (es)
BR (1) BR112012024247A2 (es)
CA (1) CA2794940A1 (es)
RU (1) RU2573384C2 (es)
WO (1) WO2011120778A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9592210B2 (en) 2011-12-22 2017-03-14 Chiesi Farmaceutici S.P.A. 1-phenylalkanecarboxylic acid derivatives for the treatment of cognitive impairment
WO2015173133A1 (en) * 2014-05-12 2015-11-19 Chiesi Farmaceutici S.P.A. Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4368198A (en) * 1976-03-03 1983-01-11 Sumitomo Chemical Company Limited Cephalosporins
EP1594833B1 (en) 2003-02-21 2008-09-24 CHIESI FARMACEUTICI S.p.A. 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
ITMI20030311A1 (it) * 2003-02-21 2004-08-22 Chiesi Farma Spa Acidi 2-fenil-2-dialchil-acetici per il trattamento della malattia di alzheimer.
US20070078114A1 (en) 2005-09-02 2007-04-05 Myriad Genetics, Incorporated Combination therapy for alzheimer's disease and other diseases
WO2008036733A2 (en) 2006-09-19 2008-03-27 Myriad Genetics, Inc. Methods for treatment of vesicle transport disorders
EP2133322A1 (en) * 2008-06-11 2009-12-16 CHIESI FARMACEUTICI S.p.A. Process of preparing derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid
SI2462098T1 (sl) 2009-08-04 2014-01-31 Chiesi Farmaceutici S.P.A. Postopek priprave derivatov 1-(2-halobifenil-4-il)-ciklopropankarboksilne kisline

Also Published As

Publication number Publication date
CN106431900A (zh) 2017-02-22
KR20130036210A (ko) 2013-04-11
WO2011120778A1 (en) 2011-10-06
US20140135399A1 (en) 2014-05-15
US20160193165A1 (en) 2016-07-07
BR112012024247A2 (pt) 2016-07-12
RU2573384C2 (ru) 2016-01-20
EP2552881A1 (en) 2013-02-06
RU2012141644A (ru) 2014-04-10
US20110245346A1 (en) 2011-10-06
CN102869643A (zh) 2013-01-09
CA2794940A1 (en) 2011-10-06
EP2647618A1 (en) 2013-10-09
US8673978B2 (en) 2014-03-18

Similar Documents

Publication Publication Date Title
ES2634490T3 (es) Derivados de ácido napht-2-ylacetico para tratar el sida
FI3351539T3 (fi) Kiteinen monohydraattikompleksi 1-syaani-2-(4-syklopropyylibentsyyli)-4-(ß-D-glukopyranos-1-yyli)bentseenistä ja L-proliinista kidevedessä (1:1:1), menetelmät sen valmistamiseksi ja sen käyttö SGLT-estäjänä
HRP20192202T1 (hr) Acc inhibitori i njihove upotrebe
HRP20171175T1 (hr) Novi triciklički spojevi
PE20120989A1 (es) Sales de disacarina, acido difumarico, acido d-1-hidroxi-2-naftoico y monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino) pirimidin-5-il) metil) fenil) acetato de 4-(dimetilamino) butilo
AR091138A1 (es) Proceso para la preparacion de n-[5-(3,5-difluorobencil)-1h-indazol-3-il]-4-(4-metilpiperazin-1-il)-2-(tetrahidropiran-4-ilamino)-benzamida
PE20120083A1 (es) Sal monotosilato del compuesto 2-metil-2-[4-(3-metil-2-oxo-8-quinolin-3-il-2, 3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]-propionitrilo en su forma cristalina a
CA2826751C (en) Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
CA2894891A1 (en) Boronic acid derivatives and therapeutic uses thereof
CA2894892A1 (en) Boronic acid derivatives and therapeutic uses thereof
AR094918A1 (es) Compuestos de tetrahidropirrolotiazina como inhibidores de bace
RU2013109393A (ru) Безилатная соль ингибитора втк
AR087107A1 (es) Compuesto inhibidor de la señalizacion de la trayectoria notch
JP2014218522A5 (es)
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
CY1122596T1 (el) Νεες φαρμακοτεχνικες μορφες (τριμεθοξυφαινυλαμινο)πυριμιδινυλιου
PE20080175A1 (es) Sales de malato, y polimorfos de acido (3s,5s)-7-[3-amino-5-metil-piperidinil]-1-ciclopropil-1,4-dihidro-8-metoxi-4-oxo-3-quinolincarboxilico
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
EA201300647A1 (ru) Оптимизированный синтез чистых неполиморфных кристаллических жёлчных кислот с заданным размером частиц
ES2650604T3 (es) Nueva forma cristalina VII de agomelatina, método de preparación y utilización de la misma, así como composición farmacéutica que la contiene
MX2013002620A (es) Novedosas n-hidroxi-benzamidas para el tratamiento del cancer.
HRP20220031T1 (hr) Kristalni trihidratni oblik (3s,3s') 4,4'-disulfanedilbis (3-aminobutan 1-sulfonske kiseline)
ES2478447T3 (es) Formulaciones del ácido desoxicólico y sus sales
AR081752A1 (es) Formas polimorficas del acido 1-(3’,4’-dicloro-2-fluorobifenil-4-il)ciclopropano carboxilico, sus sales y composiciones farmaceuticas
PE20100085A1 (es) Formas solidas de (1r,2s,3r)-1-(2-(isoxazol-3-il)-1h-imidazol-4-il)butano-1,2,3,4-tetraol y metodos de uso

Legal Events

Date Code Title Description
FB Suspension of granting procedure